Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma

8noWe report an interesting clinical case of a patient carrying a specific BRCA2 germline variant affected by bone and hepatic metastases from a high grade uterine stromal sarcoma who obtained a complete metabolic response after only 3 cycles of trabectedin treatment (1.5mg/m(2) given intravenously over 24hours every 21days). Molecular investigations linked this outstanding positive pharmacological response with the loss of heterozygosity (LOH) of the mutated BRCA2 gene. These data support the hypothesis that the response to trabectedin may be positively conditioned by the different DNA repair defects present in the neoplasm and that BRCAness tumor genotype is important in determining the efficacy of trabectedin-based chemotherapy.partially_openopenMiolo, Gianmaria; Viel, Alessandra; Canzonieri, Vincenzo; Baresic, Tania; Buonadonna, Angela; Santeufemia, Davide Adriano; Della Puppa, Lara; Corona, GiuseppeMiolo, Gianmaria; Viel, Alessandra; Canzonieri, Vincenzo; Baresic, Tania; Buonadonna, Angela; Santeufemia, Davide Adriano; Della Puppa, Lara; Corona, Giusepp